

**If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.**

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>		<b>Complete if Known</b>	
		Application Number	10/625,204
		Filing Date	07/23/03
		First Named Inventor	Carl Gustav FIGDOR
		Art Unit	Not yet assigned
		Examiner Name	Not yet assigned
Sheet 3	of 3	Attorney Docket Number	89 DIV1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
MH	K	CURTIS BM et al., "Sequence and expression of a membrane-associated C-type lectin that exhibits CD4-independent binding of human immunodeficiency virus envelope glycoprotein gp120", Proc. Natl. Acad. Sci. USA 89:8356-8360 (1992).	
	L	TSUNETSUGU-YOKOTA Y et al., "Efficient Virus Transmission from Dendritic Cells to CD4+ T Cells in Response to Antigen Depends on Close Contact through Adhesion Molecules", Virology 239:259-268 (1997).	
	M	ZOETWEIJ JP and BLAUVELT A, "HIV-Dendritic Cell Interactions Promote Efficient Viral Infection of T Cells", J. Biomed. Sci. 5:253-259 (1998).	
	N	MANCA F et al., "Dendritic Cells Are Potent Antigen-Presenting Cells for In Vitro Induction of Primary Human CD4+ T-Cell Lines Specific for HIV gp120", Journal of Acquired Immune Deficiency Syndromes 7:15-23 (1994).	
	O	KNIGHT SC and PATTERSON S, "Bone Marrow-Derived Dendritic Cells, Infection with Human Immunodeficiency Virus, and Immunopathology", Annu. Rev. Immunol. 15:593-615 (1997).	
↓	P	GENBANK Accession No. AB015629 including updates of April 17, 1999; April 20, 1999; April 20, 1999 (later time); July 26, 2001; and July 23, 2002.	

Examiner Signature	/Michelle Horning/	Date Considered	09/27/2006
--------------------	--------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08a/b (07-05)  
Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/B/PTO</b>			<b>Complete if Known</b>		
			Application Number	10/625204	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)			Filing Date	July 23, 2003	
			First Named Inventor	Carl Gustav Figdor	
			Art Unit	1648	
			Examiner Name	M. S. Horning	
Sheet	1	of	2	Attorney Docket Number	ALXN-P03-089

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
MH	AA*	US-6,605,279-B2	08-12-2003	Freeman et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	MM-DD-YYYY			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
MH	CA	Amersdorfer et al., <i>Infection and Immunity</i> , 65, pp. 3743-3752 (1997).			
	CB	Andre et al., <i>Journal of Virology</i> , 72(2), pp. 1497-1503 (1998).			
	CC	Baribaud, Frederic, et al., "Functional and Antigenic Characterization of Human, Rhesus Macaque, Pigtailed Macaque, and Murine DC-SIGN," <i>Journal of Virology</i> , 75(21), pp. 10281-10289 (2001).			
	CD	Kataoka et al., <i>Cancer Research</i> , 38(5), pp. 1202-1207 (1987) - Abstract only from Biosis database.			
	CE	Cohen, <i>Science</i> , 287, p. 1567 (2000).			
	CF	Engering, Anneke, et al., "The Dendritic Cell-Specific Adhesion Receptor DC-SIGN Internalizes Antigen for Presentation to T Cells," <i>J. of Immunol.</i> , 168, pp. 2118-2126 (2000).			
	CG	Feinberg, Hadar, et al., "Structural Basis for Selective Recognition of Oligosaccharides by DC-SIGN and SC-SIGN," <i>Science</i> , 294, pp. 2163-2166 (2001) (with Supplementary Material published electronically on the <i>Science</i> website, 6 pgs.).			
	CH	Geijtenbeek, Teunis, B.H., et al., "Identification of DC-SIGN, a Novel Dendritic Cell-Specific ICAM-3 Receptor that Supports Primary Immune Responses," <i>Cell</i> , 100, pp. 575-585 (2000).			
	CI	Geijtenbeek, Teunis, B.H., et al., <i>Cell</i> , 100, pp. 587-597 (2000).			
	CJ	Geijtenbeek, et al., "Identification of Different Binding Sites in the Dendritic Cell-Specific Receptor DC-SIGN for Intercellular Adhesion Molecule 3 and HIV-1," <i>J. Biol. Chem.</i> , 277(13), pp. 11314-11320 (2002).			
	CK	Gruber, Andreas, et al., "Functional Aspects of Binding of Monoclonal Antibody DCN46 to DC-SIGN on Dendritic Cells," <i>Immunology Letters</i> , 84, pp. 103-108 (2002).			
	CL	Harlow and Lane, <i>Antibodies: A Laboratory Manual</i> , 1988 Cold Spring Harbor Laboratory, pages 141-142.			
	CM	Janeway, Charles, A., Jr., et al., <i>Immunobiology</i> , (5th ed.), Garland Publishing, New York, p.691 (2001).			
	CN	Pohlmann, Stefan, et al., "DC-SIGN Interactions with Human Immunodeficiency Virus Type 1 and 2 and Simian Immunodeficiency Virus," <i>J. of Virology</i> , 75(10), pp. 4664-4672 (2001).			
	CO	Steinman, <i>Cell</i> , 287, pp. 491-494 (2000).			
Examiner Signature	/Michelle Horning/			Date Considered	09/27/2006

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				<b>Complete If Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Application Number	10/625204
				Filing Date	July 23, 2003
				First Named Inventor	Carl Gustav Figdor
				Art Unit	1648
				Examiner Name	M. S. Horning
Sheet	2	of	2	Attorney Docket Number	ALXN-P03-089

	CP	Toda, et al., <i>Immunology</i> , 92, pp. 111-117 (1997).	
MH	CQ	Vakeva, Antti, P., et al., "Myocardial Infarction and Apoptosis After Myocardial Ischemia and Reperfusion," <i>Circulation</i> , 97, pp. 2259-2267 (1998).	
	CR	Woodle, E.S., et al., <i>Transplantation</i> , 68, pp. 608-616 (1999).	
	CS	FDA Approves Second Indication for Monoclonal Antibody, June 28, 1993, printed on November 12, 2004 from <a href="http://www.fda.gov/bbs/topics/ANSWERS/ANS00506.html">http://www.fda.gov/bbs/topics/ANSWERS/ANS00506.html</a> , June 28, 1993.	
	CT	Product Information for Affinity Purified anti-human CD209 (DC-SIGN) antibody, from eBioscience, printed on January 5, 2004 from <a href="http://www.ebioscience.com/ebioscience/specs/antibody_14/14-2099.htm">http://www.ebioscience.com/ebioscience/specs/antibody_14/14-2099.htm</a>	
	CU	Product information for CDN46, Purified Mouse Anti-Human Monoclonal Antibody, BD PharMingen Technical Data Sheet, BD Biosciences Product Information sheet, Catalog Number 551186, 05/01/01.	
	CV	Package insert for Orthoclone OKT3 Sterile Solution (murumonab-CD3) from Ortho Biotech Products LP, Raritan, NJ, Revised March 2001.	
V	CW	Sequence Alignment of Curtis et al., PNAS 89: 8356-8360 (1992) with SEQ ID NO: 2 from U.S.S.N. 09/719,961.	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Michelle Horning/	Date Considered	09/27/2006
--------------------	--------------------	-----------------	------------